Charles River Laboratories and Atomwise leverage AI towards drug innovations
Select language to see a machine translation of this article. The original language of the Article is English and the translation is provided for your convenience.

Charles River Laboratories and Atomwise leverage AI towards drug innovations

Charles River, a major facilitator of drug development and research innovations for the pharmaceutical and biotechnology industries, has formed a “strategic alliance” with Atomwise, the inventor of the first deep learning artificial intelligence (AI) used in “small molecule drug discovery”. The partnership will combine both companies’ industry-leading drug discovery platforms to “significantly streamline the hit discovery, hit-to-lead, and lead optimisation process for clients’ research efforts.”

Charles River Laboratories’ share price has increased by 7% year to date

charles river lab g 140119

Source: Yahoo Finance

With both companies working together to make new drug discoveries easier and quicker than was previously possible, it should be a case of “everybody wins” – the clients, who get a better service and more comprehensive set of products, as well as both companies, which are set to optimise their performance in tandem. According to the press release: “Charles River’s clients can expect increased efficiency and diversity in the drug discovery process, ultimately reducing the expected timeline for an integrated drug discovery project and expanding the chemical space examined.”

Charles River’s chairman, president and CEO, James Foster, said: “As Charles River continues to expand its early drug discovery portfolio, innovative solutions, including Atomwise’s AI technology, enable us to provide clients with a comprehensive, integrated platform for their early-stage drug research. By cutting time out of each stage of the drug discovery process, we enable our clients to deliver novel therapeutics to patients more efficiently and effectively.”

The company’s corporate executive vice president of discovery and safety assessment, Birgit Girshick, added: “We are proud to put this cutting-edge technology in the hands of our scientists and clients. The potential for both time savings and program optimization represents an attractive value proposition for our clients.”

Dominion holds Charles River Laboratories in its Global Trends Managed Fund.

If you would you like to receive the Newsfeeds daily, please click here to sign up now!

Help us make this Newsfeed better by rating this article. 1 star = Poor and 5 stars = Excellent
0.0/5 rating (0 votes)

The views expressed in this article are those of the author at the date of publication and not necessarily those of Dominion Fund Management Limited. The content of this article is not intended as investment advice and will not be updated after publication. Images, video, quotations from literature and any such material which may be subject to copyright is reproduced in whole or in part in this article on the basis of Fair use as applied to news reporting and journalistic comment on events.